Stress Response Studies
Free Shipping on orders over $200
Scan the QR code on any vial to verify its batch, COA, and origin in seconds. Secure traceability from our lab to your bench.
Selank is a peptide made of seven amino acids. It is based on tuftsin, a natural immune peptide. It carries the same stabilizing tail used in Semax, and both came out of the same Russian research institute. Studies in rodent models have measured GABA signaling, which is how the brain slows activity down, along with stress-related endpoints.
Synthetic tuftsin-derived heptapeptide
The pathways Selank acts on — and what each one does. The animation traces its signal outward from the compound to every target it engages.
Research indicates Selank modulates GABAergic neurotransmission, including GABA-A receptor activity and expression of GABAergic system components. This mechanism is associated with the anxiolytic effects observed in preclinical animal models and early clinical studies, without the sedative or dependency concerns seen with classical benzodiazepines.
Raised brain-derived neurotrophic factor (BDNF) expression and altered enkephalin metabolism have been measured. BDNF is central to neuroplasticity and synaptic maintenance. Enkephalin stabilisation is one proposed mechanism behind the mood and cognitive endpoints recorded in preclinical studies.
Selank is derived from the immunomodulatory tetrapeptide tuftsin (Thr-Lys-Pro-Arg) with a proline-glycine-proline extension that raises stability. Changes in cytokine production including IL-6, IL-1β and TNF-α expression have been measured, which is why it is investigated for both neurological and immunological activity.
The main areas Selank is being studied for — and the study-reported figures behind them.
Preclinical studies demonstrate anxiolytic effects in elevated plus maze and open field tests, attributed to GABAergic modulation. Selank shows anxiolytic activity comparable to diazepam without sedative side effects in rodent models.
Learning and memory consolidation measures are recorded in animal models of stress-induced cognitive impairment. Raised BDNF and enkephalin stabilisation are proposed as the underlying mechanisms.
Studies report Selank modulates expression of interleukin-6, TNF-α, and interferon signaling pathways, consistent with its tuftsin-derived immunomodulatory origin. Investigated as a model for peptide-based neuroimmunomodulation research.
Gene expression studies identify Selank-induced changes in transcription of genes related to serotonin, dopamine metabolism and synaptic plasticity - a molecular pharmacology framework for studying peptide anxiolytics.
An interactive 3D model rendered from the compound record — rotate and explore its structure.
C33H57N11O8
| Chemical Name | Thr-Lys-Pro-Arg-Pro-Gly-Pro (Selank) |
| Sequence | H-Thr-Lys-Pro-Arg-Pro-Gly-Pro-OH |
| Molecular Weight | 751.88 Da |
| Molecular Formula | C33H57N11O8 |
| Form | Lyophilized powder |
| Purity | ≥99% (HPLC verified) |
| Testing | Third-party HPLC, Mass Spec, Endotoxin |
| Storage | -20°C for long-term stability |
| Solubility | Water or bacteriostatic water |
| COA | Included with every order |
Selank is a synthetic heptapeptide (7 amino acids) developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It is derived from the immunomodulatory tetrapeptide tuftsin (Thr-Lys-Pro-Arg), which is a natural fragment of IgG immunoglobulin. A Pro-Gly-Pro extension was added to increase the peptide's stability and half-life. Selank is approved in Russia as an anxiolytic drug for generalized anxiety disorder and neurasthenia.
Selank's anxiolytic endpoints are attributed to several mechanisms. Changes in GABA-A receptor expression and GABAergic neurotransmission have been measured, similar to but distinct from benzodiazepines. Raised BDNF, enkephalin stabilisation via enkephalinase inhibition, and altered serotonin and dopamine metabolism have also been recorded — a multi-target profile.
No. Selank is not approved by the FDA or the European Medicines Agency (EMA). It is approved in Russia under the brand name Selank for anxiety and neurasthenic conditions. Characterisation outside Russia is very limited, and most research originates from Russian institutions. It is sold here for in vitro research use only.
Selank acts on GABAergic activity through a different mechanism from benzodiazepines. In preclinical studies, anxiolytic endpoints were recorded without the sedation, motor impairment or physical dependence seen with classical benzodiazepines. In rodent models it behaves as an anxioselective agent, with anxiety-related behaviour scored separately from sedation.
Selank is derived from tuftsin, a natural tetrapeptide with well-characterised immunostimulatory activity. Changes in cytokine production (IL-6, TNF-α, interferon signalling) have been measured, and a neuroimmune bridging role is one proposed interpretation. That dual activity is why it appears in neuroimmunomodulation research on links between anxiety, stress and immune function.
Lyophilized Selank should be stored at -20°C away from moisture and light. The Pro-Gly-Pro C-terminal extension raises Selank's resistance to proteolytic degradation compared to tuftsin, giving greater stability in biological research conditions.
Not for human or veterinary use. For in-vitro laboratory research only. These statements have not been evaluated by the FDA; this product is not intended to diagnose, treat, cure, or prevent any disease. Sold exclusively to qualified researchers and institutions.
